Eight (25%) had received ROP treatment, of whom one had been treated with anti‐vascular endothelial growth factor (Lucentis/Ranibizumab) as first treatment, and seven had been treated with laser as first treatment. This evidence concerns the gene VEGFA and retinopathy of prematurity.